Panitumumab- behandlingen blev indstillet på grund af en statistisk signifikant reduktion i PFS hos patienter, som fik panitumumab, observeret ved en interimanalyse.
Panitumumab treatment was discontinued due to a statistically significant reduction in PFS in patients receiving panitumumab observed in an interim analysis.